Ptc Therapeutics Inc (PTCT) 13F Investor Activity Report (Q2 2026)

PTCT ranks #1607 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PTCT is a top-conviction position for Palo Alto Investors LP — at 10.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PTCT belongs to BlackRock, Inc., but the position matters far more to Palo Alto Investors LP, who has 10.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Assenagon Asset Management S.A. has trimmed its PTCT position for two straight quarters, cutting it by $3.7M while still holding $446.9K.

PTCT is down 0.4% today, but institutions show net buying of $1.1B this quarter — a divergence between today's price move and the underlying institutional flow.

PTCT reported a net loss of $38.4M over the trailing twelve months.

• Not yet profitable — net loss of $38.4M over the trailing twelve months
• Revenue declined 42.8% year over year
• Net income declined year over year, from $629.2M to -$38.4M
• Generated $711.2M in positive operating cash flow
• Current ratio of 2.35x — enough short-term assets to cover short-term liabilities